Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

PDE2A-IN-2

Catalog No. T214859 Copy Product Info
🥰Excellent
PDE2A-IN-2 is a selective blood-brain barrier-permeable PDE2A inhibitor (Ki = 5.49 nM) with over 100-fold selectivity for other PDE subtypes. The 11C-labeled PDE2A-IN-2 can be utilized as a positron emission tomography (PET) tracer for imaging in neurodegenerative diseases. In vitro, PDE2A-IN-2 reduces the signal of radiotracers in PDE2A-rich areas, while in vivo, it shows lower binding affinity. It is applicable in research focused on neurodegenerative conditions.

PDE2A-IN-2

Copy Product Info
🥰Excellent
Catalog No. T214859

PDE2A-IN-2 is a selective blood-brain barrier-permeable PDE2A inhibitor (Ki = 5.49 nM) with over 100-fold selectivity for other PDE subtypes. The 11C-labeled PDE2A-IN-2 can be utilized as a positron emission tomography (PET) tracer for imaging in neurodegenerative diseases. In vitro, PDE2A-IN-2 reduces the signal of radiotracers in PDE2A-rich areas, while in vivo, it shows lower binding affinity. It is applicable in research focused on neurodegenerative conditions.

PDE2A-IN-2
Cas No. 2055901-03-4
Pack SizePriceUSA StockGlobal StockQuantity
10 mgInquiry10-14 weeks10-14 weeks
50 mgInquiry10-14 weeks10-14 weeks
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
PDE2A-IN-2 is a selective blood-brain barrier-permeable PDE2A inhibitor (Ki = 5.49 nM) with over 100-fold selectivity for other PDE subtypes. The 11C-labeled PDE2A-IN-2 can be utilized as a positron emission tomography (PET) tracer for imaging in neurodegenerative diseases. In vitro, PDE2A-IN-2 reduces the signal of radiotracers in PDE2A-rich areas, while in vivo, it shows lower binding affinity. It is applicable in research focused on neurodegenerative conditions.
Targets&IC50
PDE2A:5.49 nM (Ki)
In vitro
PDE2A-IN-2 (compound 1) at a concentration of 1 μM, incubated for 30 minutes, reduces the radioactive tracer signal in PDE2A-rich areas when co-treated with its unlabeled form (1 μM), resulting in a more uniform distribution in SD rat brain slices.
In vivo
PDE2A-IN-2 (compound 1), administered as a single intravenous injection at 1 mg/kg, exhibits low binding affinity in SD rats.
Chemical Properties
Molecular Weight347.35
FormulaC17H16F3N5
Cas No.2055901-03-4
SmilesFC(F)(F)C1=CC=C(C=C1)C2(NC3=NC(=NC4=C3C=NN4C)C)CC2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy PDE2A-IN-2 | purchase PDE2A-IN-2 | PDE2A-IN-2 cost | order PDE2A-IN-2 | PDE2A-IN-2 in vivo | PDE2A-IN-2 in vitro | PDE2A-IN-2 formula | PDE2A-IN-2 molecular weight